Equities

Enzo Biochem Inc

Enzo Biochem Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.15
  • Today's Change0.02 / 1.77%
  • Shares traded115.13k
  • 1 Year change-12.21%
  • Beta0.7469
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Jul 31 2024202420232022
ASSETS
Cash And Short Term Investments528222
Total Receivables, Net3.994.814.76
Total Inventory6.837.949.52
Prepaid expenses1.842.341.82
Other current assets, total5.001.005.13
Total current assets709843
Property, plant & equipment, net151716
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.530.751.31
Total assets8612276
LIABILITIES
Accounts payable1.383.583.72
Accrued expenses6.56139.08
Notes payable/short-term debt02.510
Current portion long-term debt/capital leases0.080.080.23
Other current liabilities, total17210
Total current liabilities254013
Total long term debt0.190.274.08
Total debt0.272.864.31
Deferred income tax------
Minority interest------
Other liabilities, total4.673.164.05
Total liabilities304321
SHAREHOLDERS EQUITY
Common stock0.520.500.49
Additional paid-in capital348344339
Retained earnings (accumulated deficit)(294)(268)(289)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.891.883.15
Total equity567854
Total liabilities & shareholders' equity8612276
Total common shares outstanding525049
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.